Borocaptate sodium is a boron-containing compound that can be used as a therapeutic agent in boron neutron capture therapy (BNCT), exhibiting anticancer activity.
Borocaptate sodium (60 μg 10B/mL, 24 hours) combined with BSO enhances boron uptake and inhibits cell viability in mouse squamous carcinoma cells, rat glioma cells, and hamster lung cells, with boron uptake increasing as cell viability decreases[3].
Borocaptate sodium (55 mg/kg, i.v., single dose) selectively targets intracranial tumors in dogs and inhibits their growth[2].
References:
[1]. Bendel P, et al. Optimal detection of the neutron capture therapy agent borocaptate sodium (BSH): A comparison between and NMR[J]. Medical Psics, 2001, 28(2): 178-183.
[2]. Kraft SL, et al. Borocaptate sodium: a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11973-7.
[3]. Yoshida F, et al. Enhancement of sodium borocaptate (BSH) uptake by tumor cells induced by glutathione depletion and its radiobiological effect. Cancer Lett. 2004 Nov 8;215(1):61-7.